Dupuytrens Disease Therapeutics Market - By Type, (I, II, III), Therapeutics (Collagenase Injection, Steroids, Immune-modulators), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) - Global Forecast 2024 – 2032

Dupuytren’s Disease Market Size

Dupuytren’s disease therapeutics market size was valued at around USD 889.4 million in 2023 and is estimated to grow at 12.2% CAGR from 2024 to 2032. Dupuytren’s disease, also known as dupuytren's contracture, is a hand deformity that develops over years. It affects a layer of tissue that lies under the skin of the palm. Knots of tissue form under the skin, eventually creates a thick cord that can pull one or more fingers into a bent position.
 

The rising prevalence for dupuytren's disease is a significant driver for the market. For instance, according to the 2020 study published by the National Center for Biotechnology Information (NCBI), the global prevalence of dupuytren's disease was estimated to be about 8.2%. Thus, underscoring an urgent need for effective therapeutic solutions and the substantial market potential for treatments targeting this widespread condition. Furthermore, advancements in drug delivery technologies and rising geriatric population are also among the promoting factors advancing the growth of the market.
 

Dupuytren’s Disease Market Trends

Recent years have witnessed notable progress in the therapeutics landscape for dupuytren’s disease, marking a trend towards treatments that are both more effective and less invasive.
 

• One of the most notable advancements in dupuytren’s disease management is the use of collagenase injections. Collagenase clostridium histolyticum, an enzymes that breaks down collagen, is injected directly into the affected cords of the palmar fascia. This treatment allows for a minimally invasive approach where the enzyme softens the cord, facilitating its rupture and correction of the finger contracture.
   
• Research into gene therapy and molecular targets offers promising new avenues for dupuytren’s disease treatment. By targeting specific genes and pathways involved in the fibrosis process, scientists are exploring ways to halt or reverse the disease’s progression. Although still largely experimental, these approaches could potentially provide more precise and effective long-term solutions.
   
• The market is witnessing revenue growth, propelled by the development of novel pharmacological agents. These drugs are designed to target pathways crucial in collagen synthesis and fibrosis. Notably, tyrosine kinase inhibitors and other antifibrotic drugs are undergoing clinical trials. The goal is to provide non-invasive solutions for Dupuytren's disease by directly modulating cellular-level pathological processes.
   

Dupuytren’s Disease Therapeutics Market Analysis

Based on type, the market is segmented into type I, type II, and type III. The type II segment of the market is forecasted to reach USD 1.3 billion by 2032.
 

• The market is primarily led by type II, which stands as the most prevalent form of the disease. Type II signifies the intermediary stage, bridging the gap between the milder type I and the more severe type III conditions.
   
• Additionally, in type II, finger contracture becomes pronounced, prompting patients to actively pursue medical interventions, thereby fueling the demand for treatment solutions.
   
• Furthermore, therapeutic interventions like collagenase injections or surgery show their greatest efficacy during the type II stage, when the condition is most manageable. This contributes to the overall revenue growth of type II segment.

Based on therapeutics, the dupuytren’s disease therapeutics market is segmented into collagenase injection, steroids, immune-modulators, and other therapeutics. The collagenase injection segment accounted for USD 489.2 million in 2023.
 

• Collagenase injections are a minimally invasive treatment option for dupuytren's disease. The procedure involves a simple injection of the enzyme into the affected collagen cords, which avoids the need for surgical incisions.
   
• The collagenase enzyme specifically targets and breaks down the collagen cords responsible for the contractures, allowing for significant improvement in finger extension and hand function.
   
• Moreover, collagenase injections can be used to treat multiple fingers or joints simultaneously, making it a versatile option for patients with contractures in various parts of the hand, thereby driving market growth.
   

Based on distribution channel, the dupuytren’s disease therapeutics market is bifurcated into retail pharmacy, hospital pharmacy, and online pharmacy. The retail pharmacy segment is forecasted to reach USD 1.3 billion by 2032.
 

• Retail pharmacies offer a wide range of over-the-counter pain relievers and other therapeutic treatments that can provide symptomatic relief. Together with vast network of retail pharmacies across various geographic locations, availability of over-the-counter therapeutics aids to the revenue growth in the retail pharmacy segment.
   
• Moreover, the competitive pricing and discounted rates of dupuytren’s disease therapeutics, alongside the ready availability of generic alternatives, enhance their affordability at retail pharmacies. This affordability factor significantly bolsters the segment's revenue growth.

The growth of the dupuytren’s disease therapeutics market in the Germany is projected to reach USD 234.4 million by 2032.
 

• Germany is known for its strong emphasis on research and development (R&D). The country hosts numerous leading pharmaceutical companies and research institutions that drive innovation in medical treatments, including those for dupuytren’s disease.
   
• The German regulatory environment is conducive to the swift approval and market introduction of new medical therapies. The country’s regulatory agencies are efficient and collaborative, promoting innovation while ensuring patient safety.
   

The dupuytren’s disease therapeutics market in U.S. is expected to experience significant and promising growth from 2024 to 2032.
 

• The U.S. Food and Drug Administration (FDA) plays a critical role in approving new treatments and ensuring their safety and efficacy. The FDA’s rigorous approval process encourages innovation and ensures that new therapies, such as CCH injections, meet high standards of effectiveness and safety. This regulatory environment fosters the introduction of novel treatments and maintains high-quality standards in the market.
   

Japan dupuytren’s disease therapeutics market is anticipated to witness lucrative growth between 2024 – 2032.
 

• The Pharmaceuticals and Medical Devices Agency (PMDA) in Japan is known for its efficient regulatory processes. This allows for the timely approval of new therapies for dupuytren’s disease, facilitating quicker access to innovative treatments for patients.
   
• Japan often has access to innovative therapies and technologies through collaborations between local pharmaceutical companies and international partners. This includes cutting-edge treatments and techniques for managing dupuytren’s disease that may not yet be widely available in other markets.
   

The dupuytren’s disease therapeutics market in Saudi Arabia is expected to experience significant and promising growth from 2024 to 2032.
 

• Saudi Arabia has made significant investments in its healthcare infrastructure, leading to well-equipped hospitals and medical facilities capable of providing advanced treatments for dupuytren’s disease.
   

Dupuytren’s Disease Market Share

The dupuytren’s disease therapeutics sector is highly competitive, featuring a blend of major global players and smaller to medium-sized companies vying for market share. The market is concentrated, with Endo International plc commanding significant share of the market, primarily through its product Xiaflex. Other competitors are focusing on alternative drugs and symptomatic treatments.
 

A key component of market strategy is the ongoing introduction of innovative products through diverse technologies. Leading industry players exert substantial influence, driving progress with significant investments in R&D. Additionally, strategic partnerships and M&A activities are vital for enhancing market presence and expanding global reach, particularly amidst evolving regulatory landscapes.
 

Dupuytren’s Disease Market Companies

Some of the eminent market participants operating in the dupuytren’s disease therapeutics industry include:

• AstraZeneca PLC
• Actiza Pharmaceutical Private Limited
• Bayer AG
• Bristol-Meyers Squibb Company
• Endo International plc
• Fresenius SE & Co. KGaA
• Fortress Biotech, Inc.
• GSK plc
• Hikma Pharmaceuticals PLC
• Johnson & Johnson
• Merck & Co., Inc.
• Nantong Jinghua Pharmaceutical Co., Ltd
• Novartis AG
• LEO Pharma A/S
• Pfizer Inc.
   

Dupuytren’s Disease Industry News:

• In March 2024, Bristol Myers Squibb completed its acquisition of Karuna Therapeutics, Inc. This strategic move highlights Bristol Myers Squibb’s dedication to expanding its capabilities and advancing innovation in the therapeutic sector.
   

The dupuytren’s disease therapeutics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Type

• Type I
• Type II
• Type III

Market, By Therapeutics

• Collagenase injection
• Steroids
• Immune-modulators
• Other therapeutics

Market, By Distribution Channel

• Retail pharmacy
• Hospital pharmacy
• Online pharmacy

The above information is provided for the following regions and countries:

• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe 
• North America 
  • U.S.
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific 
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America 
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa